FRE Stock Analysis: Fresenius SE & Co. KGaA | XETRA
Medical Care Facilities | XETRA, Germany | Market Cap: 26.030m EUR | 12M Return: 1.7% | DE000FRE5EN2 | Charts, Fundamentals & Technical Analysis
Avg Turnover: 25.9M
EPS Trend: 97.3%
Qual. Beats: 0
Rev. Trend: -68.2%
Qual. Beats: 0
Warnings
Tailwinds
Seasonality 11.6 years of data
How good or bad each month usually is (without trend). The score below shows how much you can trust it: 0 = pure chance, >40 gets interesting and >55 is strong.
Fresenius SE & Co. KGaA is a German healthcare group founded in 1912 and headquartered in Bad Homburg vor der Höhe, listed on XETRA under the ticker FRE. It operates through two main segments: Fresenius Kabi, which supplies biopharmaceuticals, clinical nutrition, IV generics, IV fluids, biosimilars, and MedTech products (such as infusion pumps and apheresis machines) for critically and chronically ill patients, and Fresenius Helios, which runs hospitals, outpatient clinics, occupational health centers, and diagnostic services across multiple regions.
The company has a strategic collaboration with SAP SE and Avelios Medical GmbH to develop a cloud-native, modular hospital information system with AI integration. Freseniuss legal form is a Kommanditgesellschaft auf Aktien (KGaA), a German partnership limited by shares, reflecting its hybrid structure between a general partnership and a stock corporation.
- German hospital reform pressures Helios reimbursement and margins
- Kabi biosimilars and IV generics face US pricing competition
- Deleveraging continues post-Vamed divestiture improving balance sheet
| Net Income: 1.52b TTM > 0 and > 6% of Revenue |
| FCF/TA: 0.03 > 0.02 and ΔFCF/TA 0.46 > 1.0 |
| NWC/Revenue: 10.87% < 20% (prev 11.63%; Δ -0.76% < -1%) |
| CFO/TA 0.07 > 3% & CFO 2.96b > Net Income 1.52b |
| Net Debt (11.5b) to EBITDA (3.64b): 3.17 < 3 |
| Current Ratio: 1.28 > 1.5 & < 3 |
| Outstanding Shares: last quarter (563.2m) vs 12m ago 0.0% < -2% |
| Gross Margin: 25.25% > 18% (prev 25.40%; Δ -0.16% > 0.5%) |
| Asset Turnover: 56.29% > 50% (prev 53.79%; Δ 2.49% > 0%) |
| Interest Coverage Ratio: 8.28 > 6 (EBIT TTM 2.52b / Interest Expense TTM 304.0m) |
| A: 0.06 (Total Current Assets 11.6b - Total Current Liabilities 9.07b) / Total Assets 41.8b |
| B: 0.36 (Retained Earnings 15.0b / Total Assets 41.8b) |
| C: 0.06 (EBIT TTM 2.52b / Avg Total Assets 41.6b) |
| D: 0.92 (Book Value of Equity 19.7b / Total Liabilities 21.4b) |
| Altman-Z'' = 2.93 = A |
| DSRI: 1.13 (Receivables 6.22b/5.21b, Revenue 23.4b/22.2b) |
| GMI: 1.01 (GM 25.40% / 25.25%) |
| AQI: 0.97 (AQ_t 0.49 / AQ_t-1 0.50) |
| SGI: 1.05 (Revenue 23.4b / 22.2b) |
| TATA: -0.03 (NI 1.52b - CFO 2.96b) / TA 41.8b) |
| Beneish M = -2.89 (Cap -4..+1) = A |
As of August 29, 2026, the stock is trading at EUR 45.86 with a total of 782,487 shares traded. Over the past week, the price has changed by -1.60%, over one month by +3.51%, over three months by +24.91% and over the past year by +1.66%.
Current recommended Stop Loss: 44.60 (which is 2.7% or 1.4 ATR below the current price).
Fresenius SE & Co. KGaA has no consensus analysts rating.
P/E Trailing = 16.8231
P/E Forward = 13.7931
P/S = 1.1181
P/B = 1.3214
P/EG = 0.89
Revenue TTM = 23.4b EUR
EBIT TTM = 2.52b EUR
EBITDA TTM = 3.64b EUR
Long Term Debt = 8.33b EUR (from longTermDebt, last quarter)
Short Term Debt = 1.86b EUR (from shortTermDebt, last quarter)
Debt = 12.8b EUR (from shortLongTermDebtTotal, last quarter) + Leases 1.40b
Net Debt = 11.5b EUR (calculated: Debt 12.8b - CCE 1.28b)
Enterprise Value = 37.6b EUR (26.0b + Debt 12.8b - CCE 1.28b)
Interest Coverage Ratio = 8.28 (Ebit TTM 2.52b / Interest Expense TTM 304.0m)
EV/FCF = 25.98x (Enterprise Value 37.6b / FCF TTM 1.45b)
FCF Yield = 3.85% (FCF TTM 1.45b / Enterprise Value 37.6b)
FCF Margin = 6.18% (FCF TTM 1.45b / Revenue TTM 23.4b)
Net Margin = 6.50% (Net Income TTM 1.52b / Revenue TTM 23.4b)
Gross Margin = 25.25% ((Revenue TTM 23.4b - Cost of Revenue TTM 17.5b) / Revenue TTM)
Gross Margin QoQ = 26.07% (prev 26.38%)
Tobins Q-Ratio = 0.90 (Enterprise Value 37.6b / Total Assets 41.8b)
Interest Expense / Debt = 2.37% (Interest Expense 304.0m / Debt 12.8b)
Taxrate = 25.66% (564.0m / 2.20b)
NOPAT = 1.87b (EBIT 2.52b * (1 - 25.66%))
Current Ratio = 1.28 (Total Current Assets 11.6b / Total Current Liabilities 9.07b)
Debt / Equity = 0.65 (Debt 12.8b / totalStockholderEquity, last quarter 19.7b)
Debt / EBITDA = 3.17 (Net Debt 11.5b / EBITDA 3.64b)
Debt / FCF = 7.98 (Net Debt 11.5b / FCF TTM 1.45b)
Total Stockholder Equity = 19.3b (last 4 quarters mean from totalStockholderEquity)
RoA = 3.66% (Net Income 1.52b / Total Assets 41.8b)
RoE = 7.89% (Net Income TTM 1.52b / Total Stockholder Equity 19.3b)
RoCE = 9.11% (EBIT 2.52b / Capital Employed (Equity 19.3b + L.T.Debt 8.33b))
RoIC = 5.59% (NOPAT 1.87b / Invested Capital 33.5b)
WACC = 4.89% (E(26.0b)/V(38.8b) * Re(6.43%) + D(12.8b)/V(38.8b) * Rd(2.37%) * (1-Tc(0.26)))
Discount Rate = 6.43% (= CAPM, Blume Beta Adj.)
Shares (quarterly) Correlation: -40.89 | Cagr: 0.0%
[DCF] Terminal Value 77.97% ; FCFF base≈1.36b ; Y1≈1.56b ; Y5≈2.30b
[DCF] Fair Price = 40.93 (EV 34.6b - Net Debt 11.5b = Equity 23.1b / Shares 563.2m; r=8.35% [WACC [floored]]; 5y FCF grow 15.0% → 2.50% )
EPS Correlation: 97.26 | EPS CAGR: 16.99% | SUE: -0.59 | # QB: 0
Revenue Correlation: -68.18 | Revenue CAGR: -11.93% | SUE: 0.52 | # QB: 0
EPS current Quarter (2026-09-30): EPS=0.81 | Chg30d=+3.93% | Revisions=+17% | Analysts=4
EPS current Year (2026-12-31): EPS=3.71 | Chg30d=+3.24% | Revisions=+75% | GrowthEPS=+5.0% | GrowthRev=+3.9%
EPS next Year (2027-12-31): EPS=3.95 | Chg30d=+1.28% | Revisions=+79% | GrowthEPS=+6.5% | GrowthRev=+5.1%
[Analyst] Revisions Ratio: +81% (up=22, down=1)